Analysts Set TG Therapeutics, Inc. (TGTX) Target Price at $26.86

TG Therapeutics, Inc. (NASDAQ:TGTX) has been given an average rating of “Buy” by the twelve analysts that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $26.86.

Several equities research analysts have recently issued reports on the stock. Zacks Investment Research cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 12th. ValuEngine cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. BidaskClub upgraded shares of TG Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 16th. Finally, SunTrust Banks, Inc. reiterated a “buy” rating and set a $28.00 price objective on shares of TG Therapeutics in a research report on Tuesday, October 3rd.

Shares of TG Therapeutics (NASDAQ TGTX) traded up 14.67% during trading on Wednesday, hitting $8.60. 2,699,506 shares of the stock were exchanged. The firm has a 50 day moving average of $11.41 and a 200-day moving average of $11.23. The stock’s market cap is $535.87 million. TG Therapeutics has a 52-week low of $4.10 and a 52-week high of $15.35.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.01. The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million. TG Therapeutics had a negative net margin of 68,806.59% and a negative return on equity of 154.02%. Equities research analysts anticipate that TG Therapeutics will post ($1.84) earnings per share for the current fiscal year.

WARNING: This story was first reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://www.themarketsdaily.com/2017/10/21/analysts-set-tg-therapeutics-inc-tgtx-target-price-at-26-86.html.

Institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. increased its position in TG Therapeutics by 44.0% in the second quarter. JPMorgan Chase & Co. now owns 364,025 shares of the biopharmaceutical company’s stock worth $3,658,000 after purchasing an additional 111,155 shares during the last quarter. Goldman Sachs Group Inc. increased its position in TG Therapeutics by 152.8% in the first quarter. Goldman Sachs Group Inc. now owns 43,020 shares of the biopharmaceutical company’s stock worth $501,000 after purchasing an additional 26,001 shares during the last quarter. Dupont Capital Management Corp bought a new stake in TG Therapeutics in the second quarter worth $258,000. Ameriprise Financial Inc. bought a new stake in TG Therapeutics in the first quarter worth $1,291,000. Finally, Russell Investments Group Ltd. bought a new stake in TG Therapeutics in the first quarter worth $811,000. Institutional investors own 49.86% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply